Diagnostic	To detect or confirm the presence of an early disease state or condition of interest or Classification into disease subtypes.
Progression	Prediction of disease progression or recurrence in patients who have the disease or medical condition of interest.
Monitoring	Identification status of a disease or medical condition or for evidence of exposure to a blood test to monitor changes in the levels of specific biomarkers.
Benign	Benign tumors may grow larger but the absence of cell proliferation and invasion to other parts of the body. 60% of these tumors occur in females aged <40 years.
Borderline	A tumor is characterized by cell proliferation, a minor degree of nuclear atypia, and without stromal invasion. Occur at a younger age than carcinoma, age 45 years.
Malignant	Malignant cells proliferate nuclear atypia and stromal invasion to other parts of the body. Primarily found in elderly patients, median age of 60 years.
Early-stage	Biomarker detection focuses on identifying biomarkers that can indicate the presence of a disease or condition at its initial or early stages.
Late-stage	Biomarker detection refers to the identification and measurement of biomarkers that are associated with advanced stages of a disease or condition
Sensitivity (SN)	Identify individuals who have the disease (true positive).
Specificity (SP)	Identify individuals who do not have the disease (true negative).
Cut-off	Biomarker-oriented (or reference intervals) approach the mean of biomarker biomarkers are sets of values.
AUC	To estimate the accuracy of a diagnostic test or predictive model use the standard method to receiver operating characteristic area under the curve (ROC AUC).
Sensitivity (SSPR)	Sensitivity in terms of detecting molecular binding in SPR biosensors (referred to as surface sensitivity).